603520 Stock Overview
Engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
Zhejiang Starry Pharmaceutical Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥10.49 |
| 52 Week High | CN¥16.26 |
| 52 Week Low | CN¥7.32 |
| Beta | 0.39 |
| 11 Month Change | 13.77% |
| 3 Month Change | 29.19% |
| 1 Year Change | -33.65% |
| 33 Year Change | -76.79% |
| 5 Year Change | -52.80% |
| Change since IPO | 64.48% |
Recent News & Updates
Recent updates
There's No Escaping Zhejiang Starry Pharmaceutical Co.,Ltd.'s (SHSE:603520) Muted Revenues
Sep 30
Shareholders Can Be Confident That Zhejiang Starry PharmaceuticalLtd's (SHSE:603520) Earnings Are High Quality
May 06Market Might Still Lack Some Conviction On Zhejiang Starry Pharmaceutical Co.,Ltd. (SHSE:603520) Even After 31% Share Price Boost
Mar 12Is Zhejiang Starry PharmaceuticalLtd (SHSE:603520) Using Too Much Debt?
Feb 28Shareholder Returns
| 603520 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 13.4% | -1.5% | -2.1% |
| 1Y | -33.6% | -9.4% | 2.8% |
Return vs Industry: 603520 underperformed the CN Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 603520 underperformed the CN Market which returned 2.8% over the past year.
Price Volatility
| 603520 volatility | |
|---|---|
| 603520 Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 603520 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 603520's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 1,845 | Weiyi Shen | www.starrypharm.com |
Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products, such as levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate.
Zhejiang Starry Pharmaceutical Co.,Ltd. Fundamentals Summary
| 603520 fundamental statistics | |
|---|---|
| Market cap | CN¥4.60b |
| Earnings (TTM) | CN¥13.89m |
| Revenue (TTM) | CN¥2.37b |
331.1x
P/E Ratio1.9x
P/S RatioIs 603520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 603520 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.37b |
| Cost of Revenue | CN¥1.87b |
| Gross Profit | CN¥498.00m |
| Other Expenses | CN¥484.11m |
| Earnings | CN¥13.89m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.032 |
| Gross Margin | 21.02% |
| Net Profit Margin | 0.59% |
| Debt/Equity Ratio | 96.5% |
How did 603520 perform over the long term?
See historical performance and comparison